Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

2.35EUR
15 Dec 2017
Change (% chg)

€-0.08 (-3.10%)
Prev Close
€2.42
Open
€2.42
Day's High
€2.46
Day's Low
€2.22
Volume
2,051,235
Avg. Vol
796,166
52-wk High
€4.26
52-wk Low
€2.04

Latest Key Developments (Source: Significant Developments)

Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment
11:43am GMT 

Dec 15 (Reuters) - PHARMA MAR SA ::THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA.AFTER OPINION OF CHMP, EUROPEAN COMMISSION TO ISSUE FINAL DECISION, EXPECTED IN MARCH OR APRIL, 2018.  Full Article

Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - PHARMA MAR SA ::PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE).  Full Article

Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma
Monday, 13 Nov 2017 

Nov 13 (Reuters) - PHARMA MAR SA ::PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA.OBSERVED DISEASE CONTROL RATE AT 60 PERCENT, INCLUDING PARTIAL RESPONSES IN 12 PERCENT AND STABILIZATION IN 48 PERCENT OF CASES.‍​.  Full Article

Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - PHARMA MAR SA ::SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY.FORMAL WRITTEN DECISION FROM EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) IS EXPECTED FOLLOWING ITS DECEMBER 2017 MEETING (DEC 11 TO DEC 15).COMPANY DEEPLY SURPRISED ABOUT CHMP NEGATIVE TREND VOTE GIVEN RESULTS OF PHASE III TRIAL.CHMP NEGATIVE TREND VOTE WAS VERBALLY COMMUNICATED TO COMPANY BY EMA.  Full Article

Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - PHARMA MAR SA ::SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA.TO RECEIVE A NON-DISCLOSED UPFRONT PAYMENT AND TO BE ELIGIBLE FOR ADDITIONAL REMUNERATIONS UPON ACHIEVING REGULATORY AND SALES MILESTONES.TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SELL THE PRODUCT TO BORYUNG PHARM FOR COMMERCIAL USE.ZEPSYRE IS CURRENTLY IN LATE-STAGE CLINICAL DEVELOPMENT FOR PLATINUM-RESISTANT OVARIAN CANCER AND FOR SMALL-CELL LUNG CANCER.  Full Article

Pharma Mar 9-month net loss narrows to 14.5 mln euros YoY
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - PHARMA MAR SA ::9-MONTH REVENUE 140.4 MILLION EUROS VERSUS 139.6 MILLION EUROS YEAR AGO.9-MONTH NET LOSS 14.5 MILLION EUROS VERSUS LOSS 16.6 MILLION EUROS YEAR AGO.9-MONTH NEGATIVE EBITDA 4.6 MILLION EUROS VERSUS NEGATIVE 5.6 MILLION EUROS YEAR AGO.  Full Article

Pharma Mar reports positive results from phase II trial with PM1183 in breast cancer
Monday, 10 Oct 2016 

Pharma Mar SA : Reports positive results from phase II trial with lurbinectedin (PM1183) in patients with metastatic breast cancer .The study met the initial objective for an overall response rate (ORR) in 41 percent of patients.  Full Article

Pharma Mar and Boryung Pharm sign licensing deal for Aplidin in South Korea
Tuesday, 4 Oct 2016 

Pharma Mar SA : Pharma Mar and Boryung Pharm have signed a licensing agreement to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in South Korea . Under terms of the deal, Pharma Mar will receive an upfront payment, royalties and additional remunerations upon achieving regulatory milestones with Aplidin .PharmaMar will retain exclusive production rights and will supply the finished product to Boryung Pharm for commercial use.  Full Article

Pharma Mar submits application to EMA for Aplidin to treat multiple myeloma
Thursday, 22 Sep 2016 

Pharma Mar SA : Submits application to the European Medicines Agency (EMA) for the marketing authorization of Aplidin (plitidepsin) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma . Expects the response from EMA in the second half of 2017 .Says to get paid 4 million euros ($4.48 million) by Chugai Pharma Europe Ltd for submission of the marketing authorization application.  Full Article

Pharma Mar to recruit total of 420 patients for PM1183 Corail study
Thursday, 11 Aug 2016 

Pharma Mar SA : Says Independent Data Monitoring Committee agrees to continue pivotal study of PM1183 Corail in patients with platinum-resistant ovarian cancer and recruit all 420 patients as expected in the protocol .Says decision is based on futility analysis performed with the first 210 patients (50 percent of the total) in which safety and efficacy of PM1183 were evaluated.  Full Article

BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

* THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA